In an update presented at the Clinical Trials in Alzheimer Disease meeting in Boston, MA November 9-12, 2021, baseline characteristics from the ACT-AD (NCT04491006) and LIFT-AD (NCT04488419) clinical trials were presented. These trials are evaluating a novel small molecule (ATH-1017; Athira, Bothell, WA) that positively modulates the hepatocyte growth factor (HGF)-MET receptor neurotrophic system for […]

How an increased focus on people has helped companies survive the pandemic. As COVID has moved through the pharma industry, there has been a reshaping of the workforce. With a new premium put on people, companies have become more in tune with employee initiatives and have made a number of adjustments. A new COVID workforce, […]

While the development of cell therapies today is largely focused on oncology indications, some companies, including Athersys, envision a future where these therapies could treat other diseases and conditions, such as cardiovascular disease. B.J. Lehmann, interim CEO of Athersys, spoke with ScienceBoard.net about a recent panel that he participated in at the Cell & Gene Meeting on […]